Market revenue in 2023 | USD 535.6 million |
Market revenue in 2030 | USD 119.4 million |
Growth rate | -19.3% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care |
Key market players worldwide | Becton Dickinson & Co, BioMerieux SA, Bio-Rad Laboratories Inc, Abbott Laboratories, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Roche Holding AG, Siemens Healthineers AG ADR, Sysmex Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 47.07% in 2023. Horizon Databook has segmented the Saudi Arabia molecular diagnostics market based on hospitals, outpatient facilities, home care covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia is facing high social and geopolitical pressures due to increasing incidence of communicable & noncommunicable diseases. Noncommunicable diseases, such as Cardiovascular Diseases (CVDs) and diabetes, are increasing owing to sedentary lifestyles. Lung, colorectal, stomach, breast, and prostate cancers are major causes of cancer related deaths in the country.
High unmet clinical needs, increase in disposable incomes, and collaborations between government, local players, & international organizations (such as WHO & UN) are expected to boost the market growth, attracting the attention of key global players. In addition, the increasing prevalence of CVDs and raising awareness about it is expected to drive the market.
According to ScienceDirect, the prevalence of CVDs is estimated to reach 479,500 by 2035. In 2023, the nation is anticipated to witness a diagnosis of over 31,000 new cancer cases. Chronic diseases need constant support from diagnostics and immunoassays to make treatment possible. Hence, the growing prevalence is expected to create growth opportunities.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account